Literature DB >> 9025853

Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study.

P M Chou1, N Barquin, F Gonzalez-Crussi, C Ridaura Sanz, T Tomita, M Reyes-Mugica.   

Abstract

In view of the poor response of ependymomas to chemotherapy, it may be hypothesized that these tumors have intrinsic drug resistance to some chemotherapeutic agents. The expression of drug resistance may be specific to a single agent or may involve multiple drugs. Among several mechanisms of drug resistance, P-glycoprotein (Pgp) has been the subject of considerable attention in clinical practice. In order to assess the possible participation of Pgp in the chemotherapeutic resistance of ependymomas, 42 biopsy specimens from 35 patients with ependymoma seen at our institutions were studied by immunohistochemistry with two monoclonal antibodies: C219 (Signet) and UIC-2 (Dr. Roninson's gift). In addition, four cases were studied by polymerase chain reaction after reverse transcription to detect transcripts of Pgp. Our results showed that in 35 samples there was a positive reaction for Pgp with both antibodies; two biopsy samples were positive only with C219 and three others with UIC-2; the remaining two samples were negative with both antibodies. Of the four cases studied by RT-PCR, three showed MDR1 transcripts. These results support our hypothesis of Pgp-mediated intrinsic multidrug resistance in these tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9025853

Source DB:  PubMed          Journal:  Pediatr Pathol Lab Med        ISSN: 1077-1042


  14 in total

1.  Supratentorial extraventricular anaplastic ependymoma in a child.

Authors:  Muhammad Faisal Khilji; Rana Shoaib Hamid; Asim Qureshi
Journal:  BMJ Case Rep       Date:  2014-03-12

Review 2.  Ependymoma: new therapeutic approaches including radiation and chemotherapy.

Authors:  Thomas E Merchant; Maryam Fouladi
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

3.  Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.

Authors:  A Korshunov; R Sycheva; V Timirgaz; A Golanov
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 4.  Chemotherapy for intramedullary spinal cord tumors.

Authors:  C Balmaceda
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

5.  The history of ependymoma management.

Authors:  Kyu-Won Shim; Dong-Seok Kim; Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2009-05-21       Impact factor: 1.475

Review 6.  Childhood ependymoma: a systematic review of treatment options and strategies.

Authors:  Jacques Grill; Chastagner Pascal; Kalifa Chantal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

8.  Pediatric neurosurgery-science, art, and humility: reflection of personal experience.

Authors:  Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2013-09-07       Impact factor: 1.475

9.  Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04).

Authors:  John R Apps; Shanna Maycock; David W Ellison; Timothy Jaspan; Timothy A Ritzmann; Donald Macarthur; Conor Mallucci; Keith Wheatley; Gareth J Veal; Richard G Grundy; Susan Picton
Journal:  Neurooncol Adv       Date:  2022-04-13

10.  Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system.

Authors:  Elvis Terci Valera; Agda Karina Brodoloni Lucio-Eterovic; Luciano Neder; Carlos Alberto Scrideli; Helio Rubens Machado; Carlos Gilberto Carlotti-Junior; Rosane Gomes de Paula Queiroz; Fabio José do Nascimento Motta; Luiz Gonzaga Tone
Journal:  J Neurooncol       Date:  2007-04-12       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.